Misbehaviour of XIST RNA in Breast Cancer Cells by Sirchia, Silvia M. et al.
Misbehaviour of XIST RNA in Breast Cancer Cells
Silvia M. Sirchia
1*, Silvia Tabano
1, Laura Monti
1, Maria P. Recalcati
2, Manuela Gariboldi
3,4, Francesca R.
Grati
5, Giovanni Porta
6, Palma Finelli
2,7, Paolo Radice
3,4, Monica Miozzo
1
1Department of Medicine, Surgery and Dentistry, Medical Genetics Unit, Universita ` degli Studi di Milano, Milano, Italy, 2Laboratory of Medical Cytogenetics and
Molecular Genetics, Istituto Auxologico Italiano, Milano, Italy, 3IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milano, Italy, 4Department of Experimental
Oncology , Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy, 5Cytogenetics and Molecular Biology Unit, Laboratorio TOMA, Varese, Italy, 6Department of
Experimental and Clinical Biomedical Sciences, Universita ` dell’Insubria, Varese, Italy, 7Department of Biology and Genetics for Medical Sciences, Universita ` degli Studi di
Milano, Milano, Italy
Abstract
A role of X chromosome inactivation process in the development of breast cancer have been suggested. In particular, the
relationship between the breast cancer predisposing gene BRCA1 and XIST, the main mediator of X chromosome
inactivation, has been intensely investigated, but still remains controversial. We investigated this topic by assessing XIST
behaviour in different groups of breast carcinomas and in a panel of breast cancer cell lines both BRCA1 mutant and wild
type. In addition, we evaluated the occurrence of broader defects of heterochromatin in relation to BRCA1 status in breast
cancer cells. We provide evidence that in breast cancer cells BRCA1 is involved in XIST regulation on the active X
chromosome, but not in its localization as previously suggested, and that XIST can be unusually expressed by an active X
and can decorate it. This indicates that the detection of XIST cloud in cancer cell is not synonymous of the presence of an
inactive X chromosome. Moreover, we show that global heterochromatin defects observed in breast tumor cells are
independent of BRCA1 status. Our observations sheds light on a possible previously uncharacterized mechanism of breast
carcinogenesis mediated by XIST misbehaviour, particularly in BRCA1-related cancers. Moreover, the significant higher levels
of XIST-RNA detected in BRCA1-associated respect to sporadic basal-like cancers, opens the possibility to use XIST expression
as a marker to discriminate between the two groups of tumors.
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Introduction
X chromosome inactivation (XCI) occurs early during embryo-
genesis and XIST (X inactive specific transcript) is the key player of
the X chromosome silencing [1,2]. XCI begins with the expression
of XIST and stabilization of its noncoding RNA transcript in cis,
along the X chromosome that is destined for inactivation [3,4].
Subsequently, the inactive X (Xi) acquires the typical features of
heterochromatin: late replication, hypoacetylation of histones H3
and H4, methylation of histone H3 lysines 9 and 27, lack of
methylation of H3 lysine 4, methylation of DNA CpG islands and
concentration of the variant histone macroH2A1 [5–7]. These
epigenetic modifications appear to act synergistically and, once
established in the soma, the inactive state is clonally and stably
maintained through the subsequent cell divisions [3–6].
There is a substantial body of evidences to reveal the occurrence
of XCI alterations in breast cancer cells. Several authors noted
that some aggressive breast tumors do not show a detectable Barr
body, the cytological evidence of the Xi [8–12]. Ganesan and
colleagues [13] reported the first evidence of a communication of
the inactive X chromosome with the protein codified by BRCA1,a
main highly penetrance gene predisposing to breast and ovarian
cancer development [14]. These authors showed that XIST RNA
concentration on the Xi is supported by the BRCA1 protein and
suggested that in BRCA1-associated carcinomas the lack of X
inactivation is a consequence of BRCA1 deficiency, an assertion
reiterated by the same group in a more recent study [15].
Otherwise, we reported [16] that in breast cancer cells, in spite of
the presence of two or more X chromosomes, none of them is
functionally inactivated, irrespective of BRCA1 status, and all the
X chromosomes are copies of native active X (Xa).
Our findings were subsequently confirmed by Richardson and
collaborators [17] in basal-like breast cancers (BLC). BLC are a
distinct breast carcinomas subtype, accounting for the majority
(,70%) of BRCA1-associated cancers and ,15% of sporadic ones
[18–22]. They are high-grade, aneuploid, invasive ductal carci-
nomas that show expression of cytokeratins of the basal layer of
breast epithelium and do not express estrogen and progesterone
receptors and HER2 [17,23,24]. Richardson and colleagues [17]
described Xi loss and Xa replication as a frequent and distinctive
feature in both sporadic and BRCA1-associated BLC, whereas it
was rarely detected in non-BLC.
Eventually, the role of BRCA1 in XIST localization on Xi was
questioned by studies [25,26] that reported the absence of a
cytological overlapping between BRCA1 and Xi or XIST
territory, despite a limited, but not exclusive, BRCA1 accumula-
tion abutting Xi. In addition, in BRCA1 depleted normal and
tumor cells and in BRCA1 reconstituted cells, the BRCA1 status
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Salomon et al. [27] pointed out that BRCA1-related tumors show
heterogeneity of the XCI status, likely due to a high degree of X
chromosome instability. The Authors observed that this instability
led not only to the loss but also to an increase in the number of Xi.
We investigated some aspects of this intricate matter by
sounding out the supposed relationship between BRCA1 and
XIST expression/localisation and by assessing the nuclear XIST
behaviour in breast cancer cells. Finally, we evaluated the
occurrence of broader defects of heterochromatin in breast cancer
cells in relation to BRCA1 status.
Results
High levels of XIST RNA in BRCA1-associated breast
carcinomas
As summarized in Figure 1A, in our previous study [16] the
analysis of XCI and XIST RNA in human mammary epithelial
cells (HMEC) and in human breast cancer cell lines revealed three
distinct patterns: presence of both Xa and Xi and XIST expression
(normal, type 0); Xa replication, Xi loss and no XIST expression
(type 1); Xa replication, Xi loss and XIST expression (type 2). The
latter finding is of particular interest since XIST is the only gene
known to be exclusively expressed from the Xi under physiological
conditions [3]. Interestingly, we found that all four cell lines not
expressing XIST were BRCA1 wild-type, whereas of the two cell
lines positive for XIST expression in the absence of a Xi, one
(HCC 1937) was BRCA1
2/2 (Figure 1A). Subsequent studies
identified XIST expression in two additional BRCA1
2/2 cell lines
(MDA MB 436 and L56Br-C1) [25,26]. These findings, although
indicating that XIST expression is not necessarily related to BRCA1
status, prompted us to speculate on a possible role of BRCA1 on
XIST regulation.
To support this hypothesis we investigated, by quantitative RT-
PCR, XIST RNA levels in two groups of BLC (9 BRCA1-related
and 10 sporadic) compared to sporadic non-BLC (n=11)
(Figure 1B). In accordance with the observations by Richardson
et al. (2006), who reported a higher frequency of Xi loss and Xa
replication in BLC respect to non-BLCs, sporadic BLC exhibited a
significant lower XIST expression than sporadic non-BLC
(p=0.0002). However, such reduced expression was not apparent
in BRCA1-related BLC, that showed XIST RNA levels comparable
to those of non-BLC (p=0.23) and significantly higher than those
detected in sporadic BLC (p=0.004).
BRCA1 knockdown leads to an enhanced XIST expression
in cells with atypical XCI status
To verify the hypothesis that the lack of functional BRCA1 is
involved in the inappropriate expression of XIST from Xa, we
performed BRCA1 silencing in HMEC (XCI-type 0) and in the
following BRCA1
wt breast cancer cell lines: MDA MB 231(XCI-
type 1), T47D (XCI-type 1) and MCF7 (XCI-type 2). For RNAi-
mediated BRCA1 knockdown we used a mix of two dsRNAs,
mapping to exons 12 and 24. By immunofluorescence, we
observed a complete protein depletion in all cell lines (Figures 2
and S1A). The impact of such acute BRCA1 knockdown on XIST
expression was examined by real-time RT-PCR. The transient
BRCA1-deficit did not affect XIST expression in type 0 and type 1
cells, whereas in type 2 cells we observed a significant increase of
XIST levels, both for the spliced and unspliced RNA forms (,12
times, P,0.05) (Figures 2 and S1A).
We verified whether the expression changes in MCF7 could be
related to epigenetic modifications of the XIST promoter region.
After BRCA1 knockdown, the pyrosequencing quantitative
analysis of XIST CpGs showed demethylation (88% average
methylation in control siRNA vs 67% in BRCA1 siRNA) (Figure
S1B). In HMEC the analysis showed approximately 44% of
methylation both before and after BRCA1 siRNA (Figure S1B).
MCF7 cell line is characterized by the presence of both XIST
positive and negative sub-populations [25,26]. Thus, the increase
of XIST levels after BRCA1 silencing in this cell line might be due
to a selection of XIST-positive cells, rather than the release of
XIST regulation on Xa. However, subsequent experiments ruled
out this possibility (see paragraph ‘‘XIST RNA staining persists
with the same features after BRCA1 silencing’’). The overall results
indicate a regulatory role of BRCA1 on Xa XIST allele.
The availability of experimental models differing for XCI type,
in which we transiently repressed the expression of BRCA1,
prompted us to further investigate the role of BRCA1 on XIST
localization.
Misbehaviour of XIST RNA in MCF7 cells
We evaluated the nuclear distribution of XIST RNA in MCF7
cells compared to HMEC.
First, we analyzed XIST X chromosome coating by RNA-
FISH. Differently from normal XIST distribution observed in
HMEC, XIST RNA staining in MCF7 showed an abnormal
morphology, with a dispersed and mislocalized signal (Figure 3A),
consistently with previous reports [25,26]. Only about 32% of
MCF7 nuclei were XIST-positive and among them 49.3% showed
clustered (Figure 3A - full arrow) and 50.7% dispersed (Figure 3A
– empty arrow) XIST RNA signals.
Next, we considered the XIST RNA localisation respect to the
nuclear X chromosome territories. Combining X chromosome
painting and XIST RNA-FISH, in HMEC we observed only a
partial coating of nuclear Xi chromosome domain by XIST RNA
(Figure 3B). This finding is in line with previous observations by
Chadwick and Willard [28] indicating that the human Xi is
packaged into at least two nonoverlapping heterochromatin types:
one defined by the presence of XIST RNA, histone variant
macroH2A, and histone H3 trimethylated at lysine 27
(H3TrimK27) and the other defined by H3 trimethylated at
lysine 9, heterochromatin protein 1 (HP1) and histone 4
trimethylated at lysine 20. Differently, in MCF7 nuclei the
overlapping of XIST RNA staining and X chromosome painting
was more limited and the XIST signal often spread outside the X
chromosome territory (Figures 3B and 3C). Therefore, in this
tumor cell line XIST shows a misbehaviour, because it is expressed
by an active X chromosome and does not stably coat the XIST
expressing X chromosome.
X chromosomes status in MCF7 cells
Based on the unusual XIST behaviour observed in MCF7 cells,
we further characterized the status of X chromosomes in this cell
line.
First, we assessed X chromosomes numbering by FISH, using
both alpha-satellite and X painting probes. MCF7 cell line
displayed two major subpopulations carrying two (,55%) or three
(,38%) X chromosomes, respectively (Figure 4A).
Then, we performed a cytological evaluation of Xi by Barr body
staining. In MCF7 cell line, we did not detect the Barr body in
more than 700 examined nuclei; whereas, HMEC showed this
cytological marker in approximately 40% of nuclei (Figure 4B).
X chromosome genotyping by Quantitative Fluorescence-PCR
using 23 highly informative STRs demonstrated high levels of
homozygosity (20/23, 87%), mainly in the q arm (17/18, 94%)
(Figure 4C), whereas in HMEC homozygosity was about 38% [16
and data not shown]. Spots of heterozygosity in MCF7 were
XIST RNA in Breast Cancer
PLoS ONE | www.plosone.org 2 May 2009 | Volume 4 | Issue 5 | e5559Figure 1. XIST expression and status of X chromosomes and BRCA1 in HMEC and breast cancer cell lines, and evaluation of XIST
levels in different groups of breast carcinomas. A) Classification of HMEC and breast cancer cell lines according to XCI type, based on the
indicated X chromosome related features. BRCA1 status is also reported. B) Box-plots of the log2-transformed amounts of XIST RNA measured by
quantitative real-time RT-PCR in the indicated groups of primary human breast cancers. Each box-plot represents the first quartile (lower edge of the
box), median value (bar inside the box), third quartile (upper edge of the box), and minimum and maximum values (horizontal lines). Points at a
distance from the quartiles .1.5 times the inter-quartile range are plotted individually. Statistically significant p values between groups are reported
(Kruskal-Wallis Rank Sum test).
doi:10.1371/journal.pone.0005559.g001
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maintenance of residual segments of the homologous X chromo-
some, as shown by FISH using Xq telomeric probe (Figure 4D).
The observation of high level of homozygosity, together with the
presence of two or more X chromosomes in the absence of
detectable Barr body, is consistent with the duplication of the Xa
and the loss of the inactive one. This is in keeping with the
complete demethylation observed in MCF7 cells of X-linked genes
subjected to XCI, including AR, PGK1, POLA, OCRL [16] and
ZMYM3 (Figure 4E).
These overall results ultimately demonstrate that in all the
subpopulations present in MCF7 the native Xi is lost and all X
chromosomes are copies of the native Xa, reinforcing our previous
observations [16].
Finally, we evaluated XIST RNA origin by combined DNA and
RNA FISH. We found that the MCF7 XIST-expressing
population always displayed three X chromosomes, only one of
which colocalized with the XIST signal (Figures 3B and 3C).
Indeed, the frequency of XIST-expressing cells (32%) approached
that of cells with three X chromosomes (38%), being the slight
difference most likely due the difficulty in scoring XIST positive
nuclei with a very dispersed signal.
XIST RNA decorates a transcriptionally competent X in
MCF7 cells
To prove that in MCF7 the XIST-positive X chromosome
resembled the features of the open chromatin, this was
epigenetically and transcriptionally characterized. We targeted
Figure 2. Effects of BRCA1 RNAi on XIST expression in cells with different XCI status. HMEC (XCI type 0), MCF7 (XCI type 1) and T47D (XCI
type 2) were transfected with a mix of two BRCA1-specific siRNAs, mapping to exons 12 and 24, or a control siRNA. After 72 hrs, cells were processed
for BRCA1 immunofluorescence and RNA purification. In all panels BRCA1 is immunostained in green and nuclei are marked with DAPI. The histogram
represents quantitative RT-PCR analysis performed on cDNAs of the indicated cell lines, before and after BRCA1 silencing, using primers specific for
spliced and unspliced XIST RNA. XIST RNA levels are expressed as a ratio to GAPDH mRNA levels, after subtraction of the background signal from cDNA
synthesis reactions lacking reverse transcriptase. To facilitate comparison between cell lines with different XCI status, the XIST/GAPDH transcript ratio
was normalised relative to HMEC. Error bars represent standard deviation and the asterisks indicate statistically significant differences (p,0.05,
Student’s test).
doi:10.1371/journal.pone.0005559.g002
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following probes: genomic single locus RP11-349A16 (Xq22.3), X
painting and XIST. We took advantage on the localization of the
RP11-349A16 probe within a cytogenetically evidenced interstitial
duplication of Xq involving one of the X chromosome (data not
shown). In the cell population with three X chromosomes, two Xs
were visualized with a single RP11-349A16 signal and one with
two signals (Figure 5A). As shown in Figure 5B, DNA/RNA FISH
revealed that the XIST-positive X chromosome was one of two Xs
showing a single RP11-349A16 signal.
Given that a shift of replication timing to late in S phase is a
typical feature of Xi [1,29], we performed FISH assay using RP11-
349A16 probe on BrdU labelled cells, to verify asynchronous
replication of X chromosomes. Both the cell populations
characterized by two and three Xs showed synchronous X
replication timing (Figure 5C), without any differences between Xs
with single or double RP11-349A16 spots, whereas HMEC
displayed a normal asynchronous X chromosome replication
timing pattern (Figure 5C).
To completely characterize the chromatin signatures of the X
chromosomes, we assessed the transcription/chromatin state of the
XIST-positive X. The assay combined XIST staining and
heterogeneous nuclear RNA (hsRNA) hybridization with Cot-1
DNA probe in non-denaturing conditions on DAPI stained nuclei.
Cot-1 positive hsRNA is notably silent over the Xi and is detected
throughout the Xa, whereas DAPI exhibits a higher affinity for
heterochromatic regions [30]. In the vast majority of HMEC
nuclei, a line scan throughout the XIST-positive X showed that
the increase of the intensity of the XIST RNA signal had the same
trend of DAPI, whereas Cot-1 RNA signal was depleted
(Figure 5D). This picture is distinctive of the nucleoplasm territory
of the normal heterochromatic inactive X. Conversely, in MCF7
cells the XIST-positive X chromosome displayed overlapping of
increased Cot-1 RNA and XIST RNA signal intensities, associated
with a reduced DAPI staining (Figure 5D), a typical sign of
euchromatin and Xa (Clemson et al., 2006). Therefore, in MCF7
the colocalization of XIST RNA with an active chromatin domain,
together with the absence of X chromosome asynchronous
replication, revealed that XIST interacts with an euchromatic
X. These unexpected findings bring to light that XIST RNA is able
to decorate and to communicate also with an active X
chromosome.
XIST RNA staining persists with the same features after
BRCA1 silencing
To assess the function of BRCA1 in XIST localization, we
monitored XIST RNA distribution before and after BRCA1 acute
knockdown in cells with normal XCI state, in which XIST is
expressed by Xi (HMEC), and in cells with abnormal XCI state,
with XIST expressed by Xa (MCF7).
In HMEC, XIST RNA staining pattern in BRCA1 siRNAs-
transfected cells was indistinguishable from that observed in non-
specific siRNA-transfected cells, with an average of 97% of cells
displaying a normal XIST RNA signal (Figure 6A). Likewise, in
MCF7 cells the fraction of XIST-positive did not substantially
change after BRCA1 silencing (33% before vs 32% after silencing)
(Figure 6A) and no difference in XIST RNA staining morphology
was observed. In fact, the proportion of nuclei with dispersed and
clustered signals was similar before and after BRCA1 knockdown
(Figure 6A). Our data are consistent with previous reports [25,26]
and support the independence from BRCA1 of XIST RNA
coating on the X chromosome, also in presence of an altered XCI
status (i.e, MCF7).
Finally, the observation that BRCA1 silencing in MCF7 did not
modify the percentage of XIST-positive cells (Figure 6A) and of
cells carrying three X chromosomes (Figure 6B) allowed us to
exclude that the increased XIST RNA levels after BRCA1
knockdown (see Figure 2) was caused by the selection of the
XIST-expressing subpopulation.
Broader defects in heterochromatin are independent of
BRCA1 status
BRCA1 has been implicated in chromatin remodelling [31,32].
Accordingly, HCC1937 BRCA1
2/2 breast cancer cell line shows a
broader compromise of the heterochromatic compartment [12].
To assess whether broader defects on heterochromatin are
specifically associated with BRCA1-deficit, we evaluated the
features of whole heterochromatin in two breast cancer cell lines
with different BRCA1 constitution, MCF7 (BRCA1
wt) and
HCC1937 (BRCA1
2/2). The analysis was based on the staining
pattern of the Cot-1 RNA fraction (hsRNA), which decorates
transcriptionally active areas of DNA, using Cot-1 probe in non-
denaturing conditions [33]. As expected in normal cells [12],
HMEC had a prominent rim of heterochromatin at the nuclear
periphery, whereas both MCF7 and HCC1937 lacked this
heterochromatic feature (Figure 6C). This evidence indicates that
defects in heterochromatin compartment are a trait of breast
cancer cells, irrespective of BRCA1 status.
Discussion
Among the several roles of BRCA1, a possible interaction with
XIST RNA has been speculated. This relationship could help
explaining the gender related effect of deleterious BRCA1 germline
mutations. However, the conflicting evidences on a communica-
tion between XIST and BRCA1 [13,15,25,26] prompted us to
further investigate on this issue and on XIST behaviour in breast
cancer cells.
We found significant higher levels of XIST RNA in BRCA1-
associated, respect to sporadic BLC. In light of a previous report
that Xi loss and replication of the native Xa are common features
in BLC [17], these observations suggest an influence of BRCA1 in
regulating XIST allele on Xa. Indeed, the positive effect of BRCA1
deficit on Xa XIST expression is demonstrated in vitro by BRCA1
silencing in XCI-type 2 (Xi negative/XIST positive) MCF7 breast
cancer cell line, which leads to a significant increase of XIST levels
and promoter demethylation. This can be due to the release of
BRCA1-mediated XIST regulation on Xa. The same phenomenon
could occur also in vivo, where, however, the situation appears
more complex, since BRCA1 tumors show heterogeneity of XCI
status, caused by genetic instability that can lead not only to the
loss but also to the gain of Xi copies [27]. Irrespective of the
Figure 3. XIST RNA behaviour in HMEC and in MCF7 breast cancer cell line. A) Localisation of XIST RNA (red signal) revealed by RNA-FISH on
HMEC and MCF7 nuclei (DAPI staining). The percentages of XIST-positive (middle) and XIST-negative (bottom) MCF7 nuclei are reported. Positive cells
show different XIST distribution, clustered clouds (full arrows) or dispersed signals (empty arrows). B–D) Localisation of XIST RNA (red) respect to
nuclear X chromosome territories (blue) revealed by FISH analysis in HMEC and MCF7 nuclei. MCF7 XIST-positive nuclei always show three X
chromosome domains. In MCF7 nuclei the overlap between XIST and X chromosome territory appears more limited (panel C), respect to HMEC (panel
B) and very often spreads outside the X chromosome domain (panel D).
doi:10.1371/journal.pone.0005559.g003
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BRCA1-related vs. sporadic BLC support the interest in investi-
gating XIST expression as a possible marker to distinguish between
these two groups of tumors. Noticeably, the modification of XIST
expression induced by BRCA1 silencing in XCI-type 2 cells is not
detected in type 0 and type 1 cell lines, where Xa XIST promoter is
completely repressed [16], thus suggesting that BRCA1 transient
knockdown has no effect on a silenced Xa promoter.
Herein, we provide additional evidences that in MCF7 the Xi is
lost and all X chromosomes are copies of the native Xa, as shown
by the widespread homozygosity of X-linked STRs. The
epigenetic and transcriptional characterization of MCF7 XIST-
positive X chromosome shows active transcription and absence of
heterochromatization. Moreover, synchronous replication timing
of all X chromosomes is observed. All above findings are
signatures of an active X.
The unusual discovery of XIST expression in a cell line carrying
only native Xa copies prompted us to verify the nuclear
distribution of XIST RNA respect to the X chromosome domains
in MCF7 cells. We found a misbehaviour of XIST product
manifested as a limited and unstable coating on the X
chromosome. In light of this observation, we argue that XIST
RNA cloud in the nucleus does not prove per itself the presence of
an inactive X chromosome and conclude that the mislocalization
of XIST cannot be considered as an indirect evidence of
compromised Xi heterochromatin, in contrast to what suggested
by Pageau et al. [12].
We found that depletion of BRCA1 in both HMEC and MCF7
does not appreciably modify XIST nuclear signal morphology.
The maintenance of the XIST features after BRCA1 knockdown
in HMEC is in keeping with previous observations from
independent studies [25,26] and indicate that BRCA1 is not the
main actor driving XIST on X chromosome. This is corroborated
by the analysis of XIST RNA signal morphology in MCF7 cells
with an atypical XIST expression, which showed overlapping
patterns before and after BRCA1 silencing. Consequently, our
findings suggest a reconsideration of those conclusions of previous
studies on the communication between XIST and BRCA1
[12,13,15,17] that were based on the incorrect assumption that
the detection of the nuclear XIST cloud in tumor cells is
necessarily indicative of the presence of the native Xi.
The analysis of the nuclear distribution of XIST in normal cells
revealed a partial coating of interphase Xi chromosome domain.
This finding is in keeping with the observations of Chadwick and
Willard [28] that showed XIST RNA association exclusively with
H3TrimK27-defined heterochromatin, and not with the other
spatially distinct type of Xi heterochromatin. Given that
H3TrimK27 is a peculiar feature of Xi [28], this might explain
why in Xi negative MCF7 cells XIST RNA disperses in the
nucleus. Intriguingly, one may speculate that, in the absence of its
physiological targets, XIST could be attracted by H3TrimK27
domains outside the Xi, modifying the epigenetic status of such
regions and possibly deregulating in trans the expression of
tumorigenesis related loci.
Alterations of XCI status in cancer cells should be considered in
the context of the overall chromatin organization. Studies of the
cancer epigenome often reveal changes of chromatin status, as well
as global hypomethylation and histone deacetylation [34]. Pageau
et al. [12] speculated on a possible involvement of BRCA1 on
chromatin pattern, given its association with constitutive hetero-
chromatin-rich structures [31,32]. The Authors reported genome-
wide deficit in heterochromatin maintenance in HCC1937
BRCA1
2/2 breast cancer cell line. However, we found that global
heterochromatin defects are present in breast cancer cell lines
independently of BRCA1 status. Our data are in keeping with
previous findings [34], indicating the presence of epigenome defects
asa commonfeature oftumorcells,ratherthan auniqueassociation
between BRCA1 and global heterochromatin maintenance.
In conclusion, our study provides further evidence that BRCA1
is not involved in XIST localization and demonstrate that the
detection of XIST in a cancer cell is not indicative of the presence
of an inactive X chromosome. However, the observation of
inappropriate XIST expression/localization in cancer cells sheds
light on a possible new mechanism of breast carcinogenesis. This
mechanism might apply in particular to BRCA1-related cancer
given the observed role of BRCA1 on the regulation of XIST
expression from the Xa.
Materials and Methods
Ethics statement
All patients whose biological samples were included in the study
signed an informed consent, approved by the Independent Ethical
Committee of Istituto Nazionale dei Tumori, Milano (Italy), to
donate to the Istituto Nazionale Tumori the leftover tissue
specimens after completing diagnostic procedures for research
purposes.
Materials
Breast cancer cell lines MCF7, MDA MB 231, T47D and
HCC1937 and normal human epithelial mammary cells (HMEC)
were maintained as previously reported [16].
Frozen primary human breast carcinomas from patients with
constitutional mutations of BRCA1 and sporadic cases were
retrieved from the Biobank of the Istituto Nazionale Tumori.
The presence of BRCA1 mutations was ascertained as previously
reported [16], whereas sporadic cases were selected based on
negative family history of cancer and age of onset .40 years.
Classification of cancer samples as BLC was based on the
simultaneous negativity for the expression of estrogen receptor
(ER), progesterone receptor (PR) and HER2/Neu protein assessed
as described [35].
Interphase indirect immunofluorescence
Cells were grown in chamber slides (LAbTek II) for 48–
72 hours, rinsed with PBS, fixed and permeabilized with 4%
paraformaldehyde, 0,1% Triton X-100 for 15 min at RT and
blocked with PBS, 0,1% Triton X-100 and 5% BSA for 30 min at
Figure 4. X chromosomes characterization of MCF7 cell line. A) FISH analysis on metaphases using X painting probe. The percentages of
MCF7 cells with two (left) or three (right) X chromosomes are indicated. B) Barr body staining. The percentages of HMEC, used as positive control,
with (right) or without (left) a detectable Barr body (arrow) are indicated. No positive cell was observed in MCF7. C) High level of homozygosity (87%)
detected by genotyping of the indicated panel of STRs. D) DNA FISH using a mix of telomeric (red, green and orange) and X alpha-satellite (blue)
probes. The orange spots decorate the Xq telomeric region: two on X chromosomes, positive for X-alpha satellite probe (white arrows) and one on a
rearranged chromosome, negative for X-alpha-satellite probe (red arrow). Telomeric red and green probes were used as hybridization control. E)
Methylation analysis of ZMYM3 gene subjected to XCI (DXS6673E locus). Electropherograms show the allelic patterns obtained by PCR of HMEC and
MCF7 DNAs undigested (top) and digested with methylation-sensitive enzymes (bottom). After digestion, HMEC show a methylated allele, whereas in
MCF7 the locus is completely demethylated, resulting in the lack of amplification.
doi:10.1371/journal.pone.0005559.g004
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PLoS ONE | www.plosone.org 8 May 2009 | Volume 4 | Issue 5 | e5559Figure 5. XIST RNA cloud paints an active X chromosome in MCF7 nuclei. A) DNA FISH using the single Xq22.3 locus RP11-349A16 probe
(red), and X alpha-satellite probe (green). Cell populations with three Xs display two different hybridization patterns: two Xs with a single red spot
(white arrows) and a chromosome with two red signals (red arrow). B) Simultaneous detection of XIST RNA (green), X chromosome territory (blue)
and Xq22.3 locus (red). The X chromosome expressing XIST has one copy of the RP11-349A16 region (merge). C) Replication timing analysis. MCF7
and HMEC were briefly labelled with BrdU and analyzed by DNA FISH using the single Xq22.3 locus RP11-349A16 probe and by BrdU
immunofluorescence. The pattern of FISH staining seen in BrdU-positive cells was scored for at least 300 nuclei of each cell type: nuclei with only
‘‘singlets’’ are those in which no Xs has yet replicated; nuclei with ‘‘singlet/s+doublet/s’’ pattern contain unreplicated and replicated Xs; nuclei with
only ‘‘doublets’’ have all replicated Xs. Both MCF7 subpopulations with two and three Xs display a synchronous replication timing. D)
Characterisation of the chromatin signatures of XIST-positive X chromosome in MCF7 and HMEC, by simultaneous FISH detection of XIST RNA (red)
and Cot-1 RNA (green); DAPI nuclear staining is in blue. A line scan of fluorescence intensity (white bars) is shown for both cell types. In HMEC, the
scan plot revealed overlap of the DAPI and XIST RNA signals, whereas the Cot-1 RNA signal is depleted, as expected for an inactive X chromosome. On
the contrary, in MCF7 cells the line scan through the XIST-positive territory shows high intensity of the Cot-1 RNA signal combined with low DAPI
intensity, typical signs of euchromatin.
doi:10.1371/journal.pone.0005559.g005
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policlonal antibody (dilution 1:50, ID# 9010 Cell Signalling)
overnight at 4uC in a humidified chamber, and subsequently
washed three times for 5 min in PBS. A FITC anti-rabbit
secondary antibody (dilution 1:200, Sigma) was then applied for
2 hours at RT in a humidified chamber. Slides were washed three
times in PBS and counterstained with DAPI-antifade (Vector
laboratories).
RNA FISH
Cells were grown in chamber slides, briefly washed with both
Hank’s balanced salt solution (Euroclone) and CSK Buffer
(10 mM NaCl, 300 mM Sucrose, 3 mM MgCl2, 10 mM PIPES
pH=6,8); all steps were done on ice and solutions were prepared
with DEPC water. Slides were fixed with 4% paraformaldehyde
for 8–10 min at 4uC, treated with a solution containing CSK
Buffer, 0,5% Triton6100, 2 mM VRC (vanadyl ribonucleoside
complex, Sigma) for 10–12 min at 4uC, and incubated in 70%
ethanol for 10 min at 4uC. They were subsequently dehydrated in
70%, 85% and 100% ethanol for 5 min each at 220uC and finally
air dried. XIST probe was obtained by Long Range PCR (Long
Range PCR-Kit Expand 20 Kb PLUS PCR System – Roche)
amplifying exons 1 and 6 of XIST gene and pulling them together.
PCR primers were as following: exon 1 sense: 59 CCCAG-
CTTCTCTCGAAAGTCACTCTAAT 39; exon 1 antisense: 59
AGTGAAGGC TTATCCACCTAGTTCAGGC 39; exon 6
sense: 59 ATTCTCTCTCCTCCCCTGCGT 39; exon 6 anti-
sense: 59TGGTAGTGATGCCAGAAACTGTGA 39. PCR prod-
ucts were labeled by random priming with Cy3-dUTP (Prime-It
Fluor, Fluorescence labeling Kit – Stratagene) following the
provided protocol. Cot-1 probe was obtained labeling 100 ng of
Cot-1 DNA (1 mg/ml, Invitrogen) by Prime-It Fluor, Fluores-
cence labeling Kit with FITC-dUTP. The probes were then
ethanol precipitated, washed in 70% ethanol, air dried and
resuspended in 15 mL of hybridization buffer (50% formamide, 46
SSC, 20% dextran sulfate, 40 mM VRC, 0,4% BSA). The probes
Figure 6. XIST RNA staining patterns and global defects of heterochromatin are independent of BRCA1 status. A) Percentages of nuclei
positive for XIST RNA signal before and after BRCA1 silencing in HMEC and in MCF7. Specific signal morphology was evaluated, distinguishing
clustered and dispersed signals. HMEC always display clustered staining only. In both cell types no relevant variation was observed after siRNA
treatment. The results were reproducible in independent experiments. B) Distribution of MCF7 cell populations respect to X chromosome numbering
before and after BRCA1 knockdown. No relevant variation in the relative content of the different populations was observed after siRNA treatment.
The results were reproducible in independent experiments. C) Analysis of heterochromatin status in BRCA1 normal and mutant cells by FISH analysis
with Cot-1 probe (green) on DAPI-stained nuclei. A line scan of fluorescence intensity (white bars) is shown for each cell type. Shaded areas indicating
regions of peripheral heterochromatin are evident in the scan plot relative to HMEC, but not in those of MCF7 (BRCA1
wt) and HCC1937 (BRCA1
2/2)
breast cancer cell lines.
doi:10.1371/journal.pone.0005559.g006
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hybridization at 37uC. The slides were then washed with 50%
formamide/26SSC for 3 times at 42uC for 5 min each, and with
26 SSC for 3 times at 42uC for 5 min each and mounted with
DAPI-antifade (Vectashield).
Image analysis was performed using Soft Imaging System Cell,
Olympus Cell Family.
DNA-FISH
DNA-FISH on cells grown in chamber slides after RNA-FISH
protocol was performed as follow. Slides were washed in PBS,
treated with 4% paraformaldehyde, 0,1% Triton6100 in PBS for
10 min at RT. They were subsequently dehydrated in 70%, 85%,
100% ethanol for 5 min each at RT, air dried and hybridized
using the following probes: BAC RP11-349A16 (Xq22.3) (UCSC
Genome Database, http://genome.ucsc.edu/ ), X chromosome
alpha-satellite (Kreatech) and X chromosome painting (WCP,
Cambio). The latter probe was Biotin labelled and detected by
DEAC-streptavidin; BAC RP11-349A16 probe was labeled by
Nick-Translation Kit (Roche). DNA FISH conditions were as
reported by CAMBIO instructions.
DNA FISH was also performed on MCF7 chromosome
preparations using BAC probe RP11-349A16 and X chromosome
alpha-satellite, according to Lichter et al. [36] with minor
modifications and using Mix1 and Mix 2 ToTelVysion Multi-
color DNA Probe (Vysis) and X chromosome alpha-satellite,
according to Vysis instructions.
Replication timing assay
Replication timing analysis for X chromosome was performed
using the BAC probe RP11-349A16 as previously described [37].
RNA interference
BRCA1 knockdown was obtained by RNA interference. A mix
of two different dsRNAs was used: BRCA1-A (ID#5479, Ambion)
mapped to exon 12 and BRCA1-B, designed with Cenix Designed
siRNAs program (Ambion, www.ambion.com/siRNA), mapped to
exon 24. The BRCA1-B siRNA sequence was: 59 GGUUU-
CUUAAAGUCUGAGA 39.
BRCA1 dsRNAs were co-transfected (100 pmol BRCA1-A and
60 pmol BRCA1-B) into cell lines by reverse transfection method,
using Lipofectamine RNAiMAX (Invitrogen). Briefly, a transfec-
tion mix, containing Lipofectamine RNAiMAX was resupended
in the growth medium, incubated for 20 min RT. Cells to be
transfected were harvested with 0.25% trypsin solution and
2.5610
4 cells were added to the transfection mix and maintained
in culture for 72 hours. The Non-specific Control Pool (Dharma-
con), dsRNAs without homology to human-specific transcripts,
was used as a negative control.
RNAi experiments were performed on an unique pull of cells,
splitted in different plates for immunofluorescence, RNA and
DNA-FISH, methylation assay and Real-Time RT-PCR.
Barr Body staining
Cells were grown in chamber slides for 3 or 4 days, rinsed with
0.9% NaCl and fixed with ethanol/acetic acid (3:1v/v). Barr body
staining was performed as previously reported [38].
Real-Time RT-PCR
RNA was isolated from cultured cells using TRI-REAGENT
(Total RNA Isolation Reagent, Sigma) following the manufactur-
er’s instructions, eliminating a possible genomic DNA contami-
nation by DNA Free Kit (Ambion). 500 ng of total RNA were
retro-transcribed using the Super Script
TM III Platinum (Two-
Step qRT-PCR Kit, Invitrogen) and the obtained cDNA was used
as template for quantitative Real-Time PCR, based on TaqMan
methodology, using the ABI PRISM 7500 Fast Sequence
Detection System (Applied Biosystems). The amount of XIST
RNA was calculated using the 2
2DDCt method relative to GAPDH
housekeeping gene, selected from a pool of tested housekeeping
genes, because it showed the same amplification efficiency in a
scale of RNA concentration. Primers and probes for both XIST
and GAPDH were provided by Applied Biosystems (TaqManH
Gene Expression Assay, ID#: Hs00300535_s1 unspliced XIST,
Hs01079824_m1 spliced XIST and 4333764 spliced GAPDH).
The experiment was also performed on untranslated RNA to
verify possibile DNA contamination.
For primary human breast carcinomas, total RNA was extracted
using Trizol reagent (Life Technologies) following the manufactur-
er’s instructions and treated with DNaseI (Qiagen). RNA was
reverse-transcribed using the High-Capacity cDNA Archive Kit
(Applied Biosystems) and the expression levels of XIST were
analyzed on an ABI PRISM 7700 instrument (Applied Biosystems)
using a specific TaqManH Gene Expression Assay (ID#
Hs01079824_m1) and the TaqManH Pre-Developed Assay for the
18S ribosomal RNA housekeeping gene (part no. 4319413E) for
normalization. Data were analyzed using the Sequence Detector
v1.9 software, and statistical analyses were performed using the R-
statistical computing programming language (R Development Core
Team 2006 R: a language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna,
Austria. ISBN 3 900051- 07-0, URL http://www.R-project.org.).
Gene expression data were quantified as described by the
manufacturer and log2-transformed to obtain normally distributed
values. The log2-transformed expression was interpreted as the
differencebetween theobserved threshold cycle(Ct) of the reference
gene and that of the gene of interest. Since in our analysis the
housekeeping gene was found to be expressed at a higher level than
XIST, the computed DCt values resulted negative.
X chromosome genotyping
DNA was extracted from cultured cells using standard phenol-
chloroform-isoamylic method. X chromosome was genotyped for
the following STRs (Short Tandem Repeats) markers, selected
from the National Center for Biotechnology Information (http://
www.ncbi.nlm.nih.gov/): DXS8105, DXS996, DXS1283E,
DXS8051, MAOA.PCR1, HUMARA, DXS981, DXS6673E,
DXS6803, DXS6801, DXS6809, DXS1153, DXS178, DXS94,
DXS1348, DXS8057, DXS6854, HPRT, DXS8043, DXS8377,
DXS8011, DXS409 and Xp22. They were individually amplified
using FAM-labelled primers and the PCR products were run on
Fluorescent Capillary Systems ABI PRISM 310/3130 (Applied
Biosystem) and analyzed with GeneScan and GeneMapper
Softwares. The alleles analysis was carried out following the
criteria of QF-PCR [39] in order to detect the presence of possible
low levels of heterozygosity, related to cell population heteroge-
neity. The standard range of the peak’s area values ratio was
previously reported in a subset of STRs of our panel [39] or, for
the other markers, it was home-made set up evaluating allele ratio
from 20 voluntary donors healthy females with an informative/
heterozygous allelic pattern, calculating the short to the long area
peak ratio.
Methylation assay
To quantify the methylation levels of XIST promoter we
analyzed a region previously described as methylated on Xi
chromosome [40], using Pyrosequencing technology.
XIST RNA in Breast Cancer
PLoS ONE | www.plosone.org 11 May 2009 | Volume 4 | Issue 5 | e5559The bisulphite conversion of genomic DNA (1 mg) was obtained
using EZ DNA methylation kit (Zymo Research). After bisulphite
treatment, PCR was carried out in a final volume of 50 ml with 2.5
unit of Promega Go-Taq polymerase (Promega). The primers for
modified sequences were: sense: 59-TTGATTATTTGGTGGT-
GTGTGAG-39 (gi:37704377, 832-854) and biotinylated antisense:
59-TCATCCATCTTACCTCCCTAATTT–39 (gi:37704377,
1009-986). The PCR conditions were 40 cycles of 95uC for
30 sec, 50uC for 30 sec and 72uC for 20 sec, followed by 72uC for
5 min. 40 ml of PCR product were used for pyrosequencing assay
using the sequencing primer: 59-TTTAGATTGTGGAGGAA-
AAG-39 (gi:37704377, 906-925).
Pyrosequencing reactions were performed in the PSQ HS 96
System (Biotage), using Pyro Gold Reagent kits (Biotage).
Methylation was quantified using Pyro Q-CpG Software (Biotage)
that calculates the ratio of converted C’s (T’s) to unconverted C’s
at each CpG, giving a percentage of methylation.
The methylation status of promoter region of ZMYM3 X-linked
gene subjected to XCI (DXS6673E locus) was analyzed by PCR using
as template the genomic DNA previously digested with the
methylation sensitive enzymes HhaI and RsaI (New England
Biolabs). Primers and method are fully described in Beever et al. [41].
Supporting Information
Figure S1 Effects of BRCA1 RNAi on XIST expression and
promoter methylation status in breast cancer cell lines. A) Effects
of BRCA1 RNAi on XIST expression in MDA MB 231(XCI type
2) breast cancer cell line. Cells transfected with a mix of two
BRCA1-specific siRNAs, mapping to exons 12 and 24, or a control
siRNA. After a 72 hrs, cells were processed for BRCA1
immunofluorescence or RNA purification. BRCA1 is immuno-
stained in green and nuclei are marked with DAPI. The histogram
represents quantitative RT-PCR analysis performed on cDNA
before and after BRCA1 silencing, using primers specific for spliced
and unspliced XIST RNA. XIST levels are expressed as a ratio to
GAPDH mRNA levels after subtraction of background signal from
cDNA synthesis reactions lacking reverse transcriptase. To
facilitate comparison between cell lines with different XCI status,
the ratio of XIST:GAPDH transcripts was normalised relative to
normal HMEC. Error bars represent standard deviation. B)
Assessment of XIST promoter methylation levels, by pyrosequen-
cing, in HMEC and MCF7. The percentages of methylation at
four CpG positions before and after BRCA1 silencing are reported.
In brackets the mean methylation is indicated. The MCF7
promoter shows demethylation after BRCA1 silencing.
Found at: doi:10.1371/journal.pone.0005559.s001 (5.88 MB EPS)
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